Comparing the current results to its competitors, Ironwood Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 158.87 % year on year. The sales growth was above Ironwood Pharmaceuticals Inc 's competitors' average revenue growth of 12.81 %, achieved in the same quarter.
Ironwood Pharmaceuticals inc achieved net profit of $40.77 millions compared to a net loss of $-37.39 millions recorded in the same quarter a year ago.
Ironwood Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the market for drugs targeting short bowel syndrome (SBS). Competitors include Takeda, which distributes the GLP-2 analog teduglutide under the brand names GATTEX® in the U.S. and REVESTIVE® in Europe. Zealand Pharma A/S is developing glepaglutide, a long-acting GLP-2 analog, and plans to initiate a Phase III clinical trial in early 2026. Hanmi Pharmaceutical is developing a once-monthly GLP-2 analog currently in a Phase II clinical trial.
Due to outstanding performance in Overall company, revenue grew by 158.87 % Ironwood Pharmaceuticals inc improved its market share, to approximately 4.83 %.
May 21, 2024
Ironwood Pharmaceuticals to Present Positive Data for Apraglutide in Short Bowel Syndrome at Digestive Disease Week 2024Ironwood Pharmaceuticals, a leading gastrointestinal-focused healthcare company, is set to present late-breaking data at the upcoming 2024 Digestive Disease Week (DDW). The data presented will be based on the pivotal Phase III clinical trial known as STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients suffering from short bowel syndrome with intestinal failure (SBS-IF).Short bowel syndrome with intestinal failure is a serious condition that occurs when a significant portion of the small intestine has been removed or not functional due to ...
May 1, 2024
Ironwood Pharmaceuticals, Inc., a leading healthcare company with a primary focus on gastrointestinal (GI) disorders, is at the forefront of advancements in treatments for short bowel syndrome with intestinal failure (SBS-IF), according to the company s latest announcements. The company recently stated that they will present new data on the once-weekly treatment with Apraglutide in SBS-IF patients at the Digestive Disease Week 2024.SBS-IF is a rare chronic debilitating malabsorptive condition characterized by reduced functional intestinal capacity. According to the American Gastroenterological Association, individuals with SBS-IF often require parenteral support (PS) because the remaining portion of their sm...
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Diamedica Therapeutics Inc's business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.
Sources:
Ironwood Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ironwood Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
